ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRMD vs PRTA // FREE CASH FLOW YIELD

CorMedix Inc. (NASDAQ) VS. Prothena Corporation plc (NASDAQ) • 15-METRIC TALLY: CRMD 7 — PRTA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. PRTA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRMD PRTA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 45.50% -35.00% +80.50 CRMD /roic <GO>
EV/EBITDA & P/E Valuation 3.0x — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — — — TIE /fcf-yield <GO>
Operating Margin 48.20% -60.00% +108.20 CRMD /operating-margins <GO>
Net Profit Margin 52.30% -60.00% +112.30 CRMD /net-margins <GO>
Revenue Growth (YoY) 180.00% -65.00% +245.00 CRMD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.81 0.20 +1.61 CRMD /balance-sheet <GO>
Piotroski F-Score Quality 8/9 2/9 +6.00 CRMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.1 48.3 -11.20 PRTA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 3.5x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $443.9M $434.8M $9.1M CRMD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRMD REV PRTA REV CRMD GROSS % PRTA GROSS % CRMD FCF PRTA FCF
FY 2025 $311.7M $9.7M 88.5% — $172.8M -$163.6M
FY 2024 $43.5M $135.2M 92.7% — -$50.7M -$150.1M
FY 2023 $137.1M $91.4M — — -$38.4M -$133.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
PRTA // BETA —